

61  
RECEIVED

NOV 0 4 2003

TECH CENTER 1600/2900

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Mailstop After Final, P.O. Box 1450, Alexandria, VA 22313-1450

10-28-03  
Date

Cynthia Hagen  
Cynthia Hagen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gross, Jane A.

Serial No. : 09/627,206

Filed : July 27, 2000

For : METHODS FOR INHIBITING B LYMPHOCYTE PROLIFERATION WITH  
SOLUBLE ZTNFF4 RECEPTORS

Examiner : Zeman, Robert A.

Art Unit : 1645

Docket No. : 98-75C2

Date : October 28, 2003

Commissioner for Patents  
Mailstop After Final  
P.O. Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

ZymoGenetics, Inc. ("Zymo"), a corporation of the State of Washington, having a place of business at 1201 Eastlake Avenue East, Seattle, WA 98102, declares that it is the assignee of the above-identified application. Documentary evidence of chain of title from the original owner to Zymo has been filed with and recorded by the United States Patent and Trademark Office at Reel 012117, Frame 0067. The evidentiary documents referred to in the instant Terminal Disclaimer have been reviewed by the undersigned and it is certified that, to the best of Zymo's knowledge and belief, title is in Zymo.

11/03/2003 BABRAHA1 00000101 260290 09627206

01 FC:2814 55.00 DA


Zymo thereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of a patent granted upon Application No. 09/569,245, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period as legal title thereto and a patent granted upon Application No. 09/569,245, is commonly owned. This agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors and assigns.

Zymo does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent granted upon Application No. 09/569,245, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims cancelled by a re-examination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The undersigned represents that she is the agent of record and has the authority to execute this document on behalf of Zymo. The undersigned further declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of any patent issuing from this patent application.

Applicant claims small entity status. Please charge the fee under 37 C.F.R. §1.20(d), estimated to be \$55.00, to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this paper is enclosed.

Signed at Seattle, Washington, on October 28, 2003.

  
Michelle L. Johnson  
Patent Attorney  
Registration No. 36,352